PL-100 News
Most Popular PL-100 Story
Merck puts HIV development program on hold
Canada's Ambrilia Biopharma says that Merck has placed the development program for the HIV therapy - MK-8122 - on hold as it focuses on basic science efforts to evaluate other PL-100 prodrugs and... Read more...
Latest Headlines
- July 28, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
